Q-omics provides the consensus-scored FBXO27 profile across patient tissues and cancer cell-line models. FBXO27 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FBXO27 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, FBXO27 RNA expression shows 16,941 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where FBXO27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO27 survival associations across molecular data types. FBXO27 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO27 RNA expression–survival associations across cancer types. High FBXO27 expression shows unfavorable associations in UCEC, STAD, OV and GBM, but favorable associations in HNSC and THCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for FBXO27 RNA expression.
This table summarizes FBXO27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FBXO27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO27 shows lower tumor expression in THCA, BRCA, COAD and KIRP and higher tumor expression in HNSC and LUSC. The THCA box plot shows higher FBXO27 RNA expression in normal versus tumor tissue (log2 FC = −1.685, t-test p < 0.001).
This table shows molecular features associated with FBXO27 in patient tissues and cancer cell lines. In patient samples, FBXO27 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
